The osteocyte in CKD: New concepts regarding the role of FGF23 in mineral metabolism and systemic complications

Bone

Volumn 54, Issue 2, 2013, Pages 222-229

  Wesseling Perry, Katherine ^a   Jüppner, Harald ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chronic kidney disease; FGF23; Osteocytes; Secondary hyperparathyroidism

Indexed keywords

CALCITRIOL; CALCITRIOL DERIVATIVE; CINACALCET; DENTIN MATRIX PROTEIN 1; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; OXYGENASE; PARATHYROID HORMONE; REGULATOR PROTEIN; SCLEROSTIN; SEVELAMER; UNCLASSIFIED DRUG;

ALBRIGHT SYNDROME; BONE BIOPSY; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE TURNOVER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HUMAN; HYPERPARATHYROIDISM; KIDNEY CALCIFICATION; MORBIDITY; NONHUMAN; OSTEOCYTE; OSTEOLYSIS; OSTEOMALACIA; PHOSPHATURIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENAL OSTEODYSTROPHY; RENAL REPLACEMENT THERAPY; REVIEW;

ANIMALS; FIBROBLAST GROWTH FACTORS; HUMANS; MINERALS; OSTEOCYTES; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY;

EID: 84875820545     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.10.008     Document Type: Review

References (87)

1. ADHR Consortium Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000, 26(3):345-348.
2. Isakova T., Wahl P., Vargas G.S., Gutierrez O.M., Scialla J., Xie H., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011, 79(12):1370-1378.
3. Gutierrez O.M., Januzzi J.L., Isakova T., Laliberte K., Smith K., Collerone G., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119(19):2545-2552.
4. Gutierrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359(6):584-592.
5. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007, 18(9):2600-2608.
6. Oliveira R.B., Cancela A.L., Graciolli F.G., dos Reis L.M., Draibe S.A., Cuppari L., et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?. Clin J Am Soc Nephrol 2010, 5(2):286-291.
7. Wetmore J.B., Liu S., Krebill R., Menard R., Quarles L.D. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010, 5(1):110-116.
8. Wesseling-Perry K., Pereira R.C., Sahney S., Gales B., Wang H.J., Elashoff R., et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011, 79(1):112-119.
9. Larsson T., Nisbeth U., Ljunggren O., Jüppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003, 64(6):2272-2279.
10. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro O., Mohammadi M., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117(12):4003-4008.
11. Gutierrez O., Isakova T., Rhee E., Shah A., Holmes J., Collerone G., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005, 16(7):2205-2215.
12. Isakova T., Xie H., Yang W., Xie D., Anderson A.H., Scialla J., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011, 305(23):2432-2439.
13. Wolf M., Molnar M.Z., Amaral A.P., Czira M.E., Rudas A., Ujszaszi A., et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011, 22(5):956-966.
14. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006, 69(11):1945-1953.
15. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009, (113):S1-S130.
16. Gattineni J., Bates C., Twombley K., Dwarakanath V., Robinson M.L., Goetz R., et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009, 297(2):F282-F291.
17. Gattineni J., Twombley K., Goetz R., Mohammadi M., Baum M. Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am J Physiol Renal Physiol 2011, 301(2):F371-F377.
18. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444(7120):770-774.
19. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004, 19(3):429-435.
20. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113(4):561-568.
21. Antoniucci D.M., Yamashita T., Portale A.A. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006, 91(8):3144-3149.
22. Perwad F., Azam N., Zhang M.Y., Yamashita T., Tenenhouse H.S., Portale A.A. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005, 146(12):5358-5364.
23. Portale A.A., Booth B.E., Halloran B.P., Morris R.C. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984, 73(6):1580-1589.
24. Krajisnik T., Bjorklund P., Marsell R., Ljunggren O., Akerstrom G., Jonsson K.B., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007, 195(1):125-131.
25. Kolek O.I., Hines E.R., Jones M.D., LeSueur L.K., Lipko M.A., Kiela P.R., et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005, 289(6):G1036-G1042.
26. Isakova T., Wahl P., Vargas G.S., Gutierrez O.M., Scialla J., Xie H., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011.
27. Ferreira A., Frazao J.M., Monier-Faugere M.C., Gil C., Galvao J., Oliveira C., et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008, 19(2):405-412.
28. Lobao R., Carvalho A.B., Cuppari L., Ventura R., Lazaretti-Castro M., Jorgetti V., et al. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol 2004, 62(6):432-439.
29. Bakkaloglu S.A., Wesseling-Perry K., Pereira R.C., Gales B., Wang H.J., Elashoff R.M., et al. Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol 2010, 5(10):1860-1866.
30. Atkins D., Peacock M. A comparison of the effects of the calcitonins, steroid hormones and thyroid hormones on the response of bone to parathyroid hormone in tissue culture. J Endocrinol 1975, 64(3):573-583.
31. Lee K., Deeds J.D., Bond A.T., Jüppner H., bou-Samra A.B., Segre G.V. In situ localization of PTH/PTHrP receptor mRNA in the bone of fetal and young rats. Bone 1993, 14(3):341-345.
32. Sabbagh Y., Graciolli F.G., O'Brien S., Tang W., Dos Reis L.M., Ryan S., et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012, 27(8):1757-1772.
33. Wesseling-Perry K., Pereira R.C., Tseng C.H., Elashoff R., Zaritsky J.J., Yadin O., et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2012, 7(1):146-152.
34. Wesseling-Perry K., Harkins G.C., Wang H.J., Elashoff R., Gales B., Horwitz M.J., et al. The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). J Clin Endocrinol Metab 2010, 95(6):2772-2780.
35. Sebastian E.M., Suva L.J., Friedman P.A. Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure. Bone 2008, 43(6):1022-1030.
36. Malluche H., Faugere M.C. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990, 38(2):193-211.
37. Kuizon B.D., Goodman W.G., Jüppner H., Boechat I., Nelson P., Gales B., et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 1998, 53(1):205-211.
38. Kuizon B.D., Salusky I.B. Intermittent calcitriol therapy and growth in children with chronic renal failure. Miner Electrolyte Metab 1998, 24(4):290-295.
39. Lund R.J., Davies M.R., Brown A.J., Hruska K.A. Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol 2004, 15(2):359-369.
40. Pereira R.C., Jüppner H., Azucena-Serrano C.E., Yadin O., Salusky I.B., Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009, 45(6):1161-1168.
41. Rhee Y., Bivi N., Farrow E., Lezcano V., Plotkin L.I., White K.E., et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 2011, 49(4):636-643.
42. Wesseling-Perry K., Pereira R.C., Sahney S., Gales B., Wang H.J., Elashoff R., et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2010.
43. Munns C.F., Rauch F., Travers R., Glorieux F.H. Three children with lower limb fractures and a mineralization defect: a novel bone fragility disorder?. Bone 2004, 35(5):1023-1028.
44. Groothoff J.W., Offringa M., Van Eck-Smit B.L., Gruppen M.P., Van De Kar N.J., Wolff E.D., et al. Severe bone disease and low bone mineral density after juvenile renal failure. Kidney Int 2003, 63(1):266-275.
45. Gomes S.A., dos Reis L.M., de O.I., Noronha I.L., Jorgetti V., Heilberg I.P. Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate[corrected]: an improved method for immunohistochemistry. J Bone Miner Metab 2008, 26(1):110-113.
46. Levin A., Bakris G.L., Molitch M., Smulders M., Tian J., Williams L.A., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71(1):31-38.
47. Liu S., Zhou J., Tang W., Menard R., Feng J.Q., Quarles L.D. Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab 2008, 295(2):E254-E261.
48. Lorenz-Depiereux B., Schnabel D., Tiosano D., Hausler G., Strom T.M. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 2010, 86(2):267-272.
49. Mackenzie N.C., Zhu D., Milne E.M., van 't Hof R., Martin A., Quarles D.L., et al. Altered bone development and an increase in FGF-23 expression in Enpp1(-/-) mice. PLoS One 2012, 7(2):e32177.
50. Sherrard D.J., Hercz G., Pei Y., Maloney N.A., Greenwood C., Manuel A., et al. The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int 1993, 43(2):436-442.
51. Gowen L.C., Petersen D.N., Mansolf A.L., Qi H., Stock J.L., Tkalcevic G.T., et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 2003, 278(3):1998-2007.
52. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32(5 Suppl. 3):S112-S119.
53. Goodman W.G., Goldin J., Kuizon B.D., Yoon C., Gales B., Sider D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342(20):1478-1483.
54. Oh J., Wunsch R., Turzer M., Bahner M., Raggi P., Querfeld U., et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002, 106(1):100-105.
55. Milliner D.S., Zinsmeister A.R., Lieberman E., Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990, 38(5):931-936.
56. Litwin M., Wuhl E., Jourdan C., Trelewicz J., Niemirska A., Fahr K., et al. Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol 2005, 16(5):1494-1500.
57. Chavers B.M., Li S., Collins A.J., Herzog C.A. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int 2002, 62(2):648-653.
58. Shroff R.C., McNair R., Figg N., Skepper J.N., Schurgers L., Gupta A., et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008, 118(17):1748-1757.
59. Shroff R.C., McNair R., Skepper J.N., Figg N., Schurgers L.J., Deanfield J., et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010, 21(1):103-112.
60. Russo D., Palmiero G., De Blasio A.P., Balletta M.M., Andreucci V.E. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004, 44(6):1024-1030.
61. Wesseling-Perry K., Pereira R.C., Tseng C.H., Elashoff R., Zaritsky J.J., Yadin O., et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2012, 7(1):146-152.
62. Shanahan C.M. Mechanisms of vascular calcification in renal disease. Clin Nephrol 2005, 63(2):146-157.
63. Ducy P., Zhang R., Geoffroy V., Ridall A.L., Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997, 89(5):747-754.
64. Moe S.M., Duan D., Doehle B.P., O'Neill K.D., Chen N.X. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003, 63(3):1003-1011.
65. Jono S., McKee M.D., Murry C.E., Shioi A., Nishizawa Y., Mori K., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000, 87(7):E10-E17.
66. Villa-Bellosta R., Bogaert Y.E., Levi M., Sorribas V. Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification. Arterioscler Thromb Vasc Biol 2007, 27(5):1030-1036.
67. Ahmed S., O'Neill K.D., Hood A.F., Evan A.P., Moe S.M. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001, 37(6):1267-1276.
68. Bostrom K. Insights into the mechanism of vascular calcification. Am J Cardiol 2001, 88(2A):20E-22E.
69. Moe S.M., O'Neill K.D., Duan D., Ahmed S., Chen N.X., Leapman S.B., et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002, 61(2):638-647.
70. Chen N.X., O'Neill K.D., Duan D., Moe S.M. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002, 62(5):1724-1731.
71. Schinke T., Amendt C., Trindl A., Poschke O., Muller-Esterl W., Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996, 271(34):20789-20796.
72. Sweatt A., Sane D.C., Hutson S.M., Wallin R. Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J Thromb Haemost 2003, 1(1):178-185.
73. Schafer C., Heiss A., Schwarz A., Westenfeld R., Ketteler M., Floege J., et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003, 112(3):357-366.
74. Faul C., Amaral A.P., Oskouei B., Hu M.C., Sloan A., Isakova T., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121(11):4393-4408.
75. Razzaque M.S., Sitara D., Taguchi T., St-Arnaud R., Lanske B. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 2006, 20(6):720-722.
76. Srivaths P.R., Goldstein S.L., Silverstein D.M., Krishnamurthy R., Brewer E.D. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 2011, 26(6):945-951.
77. Lim K., Lu T.S., Molostvov G., Lee C., Lam F., Zehnder D., et al. Vascular Klotho Deficiency Potentiates the Development of Human Artery Calcification and Mediates Resistance to FGF-23. Circulation 2012, 125(18):2243-2255.
78. Hu M.C., Shi M., Zhang J., Quinones H., Griffith C., Kuro-o M., et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011, 22(1):124-136.
79. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003, 349(5):446-456.
80. Teng M., Wolf M., Ofsthun M.N., Lazarus J.M., Hernan M.A., Camargo C.A., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005, 16(4):1115-1125.
81. Nagano N., Miyata S., Abe M., Kobayashi N., Wakita S., Yamashita T., et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006, 69(3):531-537.
82. Wesseling-Perry K., Harkins G.C., Wang H., Elashoff R.M., Gales B., Horwitz M.J., et al. The calcemic response to continous PTH(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). J Clin Endocrinol Metab 2010.
83. Lavi-Moshayoff V., Wasserman G., Meir T., Silver J., Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010, 299(4):F882-F889.
84. Parker B.D., Schurgers L.J., Brandenburg V.M., Christenson R.H., Vermeer C., Ketteler M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010, 152(10):640-648.
85. Gonzalez-Parra E., Gonzalez-Casaus M.L., Galan A., Martinez-Calero A., Navas V., Rodriguez M., et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant 2011.
86. Koizumi M., Komaba H., Nakanishi S., Fujimori A., Fukagawa M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2012, 27(2):784-790.
87. Bacchetta J., Dubourg L., Harambat J., Ranchin B., Abou-Jaoude P., Arnaud S., et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 2010, 95(4):1741-1748.